Advertisement

COVISHIELD News

alt
According to AstraZeneca, the vaccination has been replaced by revised shots that address novel variations. 
alt
TTS is thrombosis with thrombocytopenia syndrome, which is a clot in blood vessels of the brain or elsewhere, along with a low platelet count TTS has emerged as a rare but significant concern associated with the AstraZeneca Covid-19 vaccine A doctor, however, emphasised that these findings don't change the fact that the vaccines were essential to fight COVID-19
alt
A man has filed a petition seeking a response from the makers of Covishield claiming that the vaccine caused his daughter's death He has demanded a compensation of Rs 1,000 crore from the Indian-vaccine maker Serum Institute of India (SII)
alt
Govt clears Corbevax as Covid-19 booster dose for adults vaccinated with Covaxin, Covishield Health Ministry's approval is based on the recommendations made by the NTG Corbevax is currently being used to inoculate children in the age group of 12 to 14 years under the COVID-19 immunisation programme.
alt
CORBEVAX has become the first vaccine in India to get DCGI approval for COVID-19 booster dose. People who are 18 years & above & have already taken two doses of either COVISHIELD or COVAXIN can now receive a dose of CORBEVAX. The vaccine can be taken after 6 months of two doses of Covaxin or Covishield vaccines for restricted use in emergency situation.
alt
Monkeypox outbreak: Social media posts claiming the chimpanzee adenovirus vector used in AstraZeneca's Covid vaccine, causes Monkeypox have surfaces, PTI reported.
alt
Sputnik booster dose has been approved in India. Over 6.5 lakh people who have received Sputnik vaccine will be eligible to take the booster dose. India had earlier approved a third dose of COVID vaccines – Covaxin and Covishield – for adults.
alt
Several vials of Covid vaccine found in a garbage dump in UP. A probe has been ordered in this regard. A vial of Covishield is opened only when 10 patients are available to take the dose.
alt
Government have decided to allow Coronavirus booster shots to all adults from Sunday The third jab will not be free for most adults Mr Poonawala said that Serum Institute will offer large discounts to hospitals and distributors
alt
Speaking to reporters on the sidelines of the ‘Alternate Fuel Conclave’, the SII CEO said the reason behind the low number of Covid-19 cases at the moment is that the country chose the right vaccine.
alt
India's apex body on immunisation NTAGI has recommended administering the second dose of Covishield between eight and 16 weeks after the first dose.
alt
The National Technical Advisory Group on Immunisation has recommended reducing the Covishield dose gap. Presently, the second dose of Covishield is being administered 12-16 weeks after the first dose. India continues on a downward trend of new Covid cases.
alt
Health ministry has denied Covishield doses going to waste reports. The health ministry said states were advised that no vaccine dose gets expired.
alt
Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year Serum Institue of India had submitted application to DCGI seeking regular market approval for Covishiled
alt
An expert panel of India's central drug authority on Wednesday recommended granting regular market approval to Covid vaccines Covishield and Covaxin, which are currently only authorised for emergency use in the country, subject to certain conditions, official sources said.
alt
A total of 330 volunteers, who were not vaccinated and had no history of the COVID-19 infection, were selected and screened for SARS-CoV-2 antibodies for the study.
alt
Scientific data available says that vaccines provide antibodies, said Dr JA Jayala It will be preventing you and helping you to come out of the severe infection, said Jayala
alt
The SII has recently filed an application with the DCGI regarding approval for a booster dose of Covishield It cited that there is adequate stock of the Covid vaccine in the country A demand for a booster shot is there due to the emergence of new coronavirus variants
alt
SII cited adequate stock of the vaccine in the country and a demand for a booster.






Loading...
english news
NEWS ON ONE CLICK